生物醫藥技術全國重點實驗室
（香港大學）
State Key Laboratory of Pharmaceutical Biotechnology
（The University of Hong Kong)
Field of Research
Metabolic dysfunction-associated steatotic liver disease (MASLD) /steatohepatitis (MASH)
Biography
Dr. Yaqian XUE is currently a Post-doctoral Fellow at the Department of Medicine, School of Clinical Medicine, The University of Hong Kong. She received her Ph.D. in Biochemistry & Molecular Biology, with a focus on metabolic diseases, from the Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences. She obtained her Bachelor of Science degree from Hebei Agricultural University. Her postdoctoral research is centered on elucidating novel molecular mechanisms and identifying biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and dyslipidemia. Her research employs a multi-disciplinary approach spanning human biomarker discovery, genetic animal models, and molecular cell biology to advance the understanding and treatment of metabolic diseases.
Publications
-
Xue Y#, Cui A#, Wei S, Ma F, Liu Z, Fang X, Huo S, Sun X, Li W, Hu Z, Liu Y, Cai G, Su W, Zhao J, Yan X, Gao C, Wen J, Zhang H, Li H, Liu Y, Lin X, Xu Y, Fu W*, Fang J*, Li Y*. Proline hydroxylation of CREB-regulated transcriptional coactivator 2 controls hepatic glucose metabolism. Proc Natl Acad Sci U S A. Epub 2023 May 30.
-
Cui A#, Xue Y#, Su W#, Lin J, Liu Y, Cai G, Wan Q, Jiang Y, Ding D, Zheng Z, Wei S, Li W, Shen J, Wen J, Huang M, Zhao J, Zhang X, Zhao Y, Li H, Ying H, Zhang H, Bi Y, Chen Y, Xu A, Xu Y, Li Y. Glucose regulation of adipose tissue browning by CBP/p300- and HDAC3-mediated reversible acetylation of CREBZF. Proc Natl Acad Sci U S A. 2024 Apr 16.
-
Chui ZSW#, Xue Y#, Xu A. Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease. Med Rev (2021). 2024 Mar 19;4(2):158-168.